Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2020 | Breast Cancer | Research

New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells

Authors: Cristina Alexandra Ciocan-Cartita, Ancuta Jurj, Oana Zanoaga, Roxana Cojocneanu, Laura-Ancuta Pop, Alin Moldovan, Cristian Moldovan, Alina Andreea Zimta, Lajos Raduly, Cecilia Pop-Bica, Mihail Buse, Liviuta Budisan, Piroska Virag, Alexandru Irimie, Sandra Martha Gomes Dias, Ioana Berindan-Neagoe, Cornelia Braicu

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2020

Abstract

Background

Triple negative breast cancer (TNBC) is a heterogeneous disease with aggressive behavior and an unfavorable prognosis rate. Due to the lack of surface receptors, TNBC must be intensely investigated in order to establish a suitable treatment for patients with this pathology. Chemoresistance is an important reason for therapeutic failure in TNBC.

Method

The aim of this study was to investigate the effect of doxorubicin in TNBC cell lines and to highlight cellular and molecular alterations after a long exposure to doxorubicin.

Results

The results revealed that doxorubicin significantly increased the half maximal inhibitory concentration (IC₅₀) values at P12 and P24 compared to parenteral cells P0. Modifications in gene expression were investigated through microarray technique, and for detection of mutational pattern was used Next Generation Sequencing (NGS). 196 upregulated and 115 downregulated genes were observed as effect of multiple dose exposure, and 15 overexpressed genes were found to be involved in drug resistance. Also, the presence of some additional mutations in both cell lines was observed.

Conclusion

The outcomes of this research may provide novel biomarkers for drug resistance in TNBC. Also, this activity can highlight the potential mechanisms associated with drug resistance, as well as the potential therapies to counteract these mechanisms.

Available only for authorised users

Hudis CA, Gianni L. Triple-negative breast cancer: an unmet medical need. Oncologist. 2011;16(Suppl 1):1–11. https://doi.org/10.1634/theoncologist.2011-S1-01.CrossRefPubMed

Braicu C, Raduly L, Morar-Bolba G, Cojocneanu R, Jurj A, Pop LA, Pileczki V, Ciocan C, Moldovan A, Irimie A, Eniu A, Achimas-Cadariu P, Paradiso A, et al. Aberrant miRNAs expressed in HER-2 negative breast cancers patient. J Exp Clin Cancer Res. 2018;37:257. https://doi.org/10.1186/s13046-018-0920-2.CrossRefPubMedPubMedCentral

Tormo E, Ballester S, Adam-Artigues A, Burgués O, Alonso E, Bermejo B, Menéndez S, Zazo S, Madoz-Gúrpide J, Rovira A, Albanell J, Rojo F, Lluch A, et al. The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors. Scientific Rep. 2019;9:5316. https://doi.org/10.1038/s41598-019-41472-y.CrossRef

Lajos R, Braicu C, Jurj A, Chira S, Cojocneanu-Petric R, Pileczki V, Berindan-Neagoe I. A miRNAs profile evolution of triple negative breast cancer cells in the presence of a possible adjuvant therapy and senescence inducer. J Buon. 2018;23:692–705.PubMed

Braicu C, Chiorean R, Irimie A, Chira S, Tomuleasa C, Neagoe E, Paradiso A, Achimas-Cadariu P, Lazar V, Berindan-Neagoe I. Novel insight into triple-negative breast cancers, the emerging role of angiogenesis, and antiangiogenic therapy. Expert Rev Mol Med. 2016;18:e18. https://doi.org/10.1017/erm.2016.17.CrossRefPubMed

Pileczki V, Pop L, Braicu C, Budisan L, Bolba Morar G, Del CM-BP, Sandulescu RV, Berindan-Neagoe I. Double gene siRNA knockdown of mutant p53 and TNF induces apoptosis in triple-negative breast cancer cells. Onco Targets Ther. 2016;9:6921–33. https://doi.org/10.2147/ott.S110719.CrossRefPubMedPubMedCentral

Duan Z, Duan Y, Lamendola DE, Yusuf RZ, Naeem R, Penson RT, Seiden MV. Overexpression of MAGE/GAGE genes in paclitaxel/doxorubicin-resistant human cancer cell lines. Clin Cancer Res. 2003;9(7):2778–85.

Krausz AE, Adler BL, Makdisi J, Schairer D, Rosen J, Landriscina A, Navati M, Alfieri A, Friedman JM, Nosanchuk JD, Rodriguez-Gabin A, Ye KQ, McDaid HM, et al. Nanoparticle-encapsulated doxorubicin demonstrates superior tumor cell kill in triple negative breast cancer subtypes intrinsically resistant to doxorubicin. Precision Nanomed. 2018;1:173–82. https://doi.org/10.33218/prnano1(3).181029.1.CrossRef

Chiorean R, Braicu C, Berindan-Neagoe I. Another review on triple negative breast cancer. Are we on the right way towards the exit from the labyrinth? Breast. 2013;22:1026–33. https://doi.org/10.1016/j.breast.2013.08.007.CrossRefPubMed

10.

Marinello PC, Panis C, Silva TNX, Binato R, Abdelhay E, Rodrigues JA, Mencalha AL, Lopes NMD, Luiz RC, Cecchini R, Cecchini AL. Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes. Sci Rep. 2019;9:5864. https://doi.org/10.1038/s41598-019-42357-w.CrossRefPubMedPubMedCentral

11.

Ciocan-Cȃrtiţă CA, Jurj A, Raduly L, Cojocneanu R, Moldovan A, Pileczki V, Pop LA, Budişan L, Braicu C, Korban SS, Berindan-Neagoe I. New perspectives in triple-negative breast cancer therapy based on treatments with TGFβ1 siRNA and doxorubicin. Mol Cell Biochem. 2020. https://doi.org/10.1007/s11010-020-03881-w.

12.

Han J, Lim W, You D, Jeong Y, Kim S, Lee JE, Shin TH, Lee G, Park S. Chemoresistance in the human triple-negative breast cancer cell line MDA-MB-231 induced by doxorubicin gradient is associated with epigenetic alterations in histone deacetylase. J Oncol. 2019;2019:1345026. https://doi.org/10.1155/2019/1345026.CrossRefPubMedPubMedCentral

13.

Pop-Bica C, Gulei D, Cojocneanu-Petric R, Braicu C, Petrut B, Berindan-Neagoe I. Understanding the role of non-coding RNAs in bladder Cancer: from dark matter to valuable therapeutic targets. Int J Mol Sci. 2017;18. https://doi.org/10.3390/ijms18071514.

14.

Jurj A, Pop LA, Zanoaga O, Ciocan-Cârtiţă CA, Cojocneanu R, Moldovan C, Raduly L, Pop-Bica C, Trif M, Irimie A, Berindan-Neagoe I, Braicu C. New insights in gene expression alteration as effect of paclitaxel drug resistance in triple negative breast cancer cells. Cell Physiol Biochem. 2020;54:648–64. https://doi.org/10.33594/000000246.CrossRefPubMed

15.

Parca L, Pepe G, Pietrosanto M, Galvan G, Galli L, Palmeri A, Sciandrone M, Ferrè F, Ausiello G, Helmer-Citterich M. Modeling cancer drug response through drug-specific informative genes. Sci Rep. 2019;9:15222. https://doi.org/10.1038/s41598-019-50720-0.CrossRefPubMedPubMedCentral

16.

Perde-Schrepler M, Fischer-Fodor E, Virag P, Brie I, Cenariu M, Pop C, Valcan A, Gurzau E, Maniu A. The expression of copper transporters associated with the ototoxicity induced by platinum-based chemotherapeutic agents. Hear Res. 2020;388:107893. https://doi.org/10.1016/j.heares.2020.107893.CrossRefPubMed

17.

Belmans N, Gilles L, Vermeesen R, Virag P, Hedesiu M, Salmon B, Baatout S, Lucas S, Lambrichts I, Jacobs R, Moreels M. Quantification of DNA double Strand breaks and oxidation response in children and adults undergoing dental CBCT scan. Sci Rep. 2020;10:2113. https://doi.org/10.1038/s41598-020-58746-5.CrossRefPubMedPubMedCentral

18.

Goidescu IG, Caracostea G, Eniu DT, Stamatian FV. Prevalence of deleterious mutations among patients with breast cancer referred for multigene panel testing in a Romanian population. Clujul Med (1957). 2018;91:157–65. https://doi.org/10.15386/cjmed-894.CrossRef

19.

Li G, Guo X, Chen M, Tang L, Jiang H, Day JX, Xie Y, Peng L, Xu X, Li J, Wang S, Xiao Z, Dai L, et al. Prevalence and spectrum of AKT1, PIK3CA, PTEN and TP53 somatic mutations in Chinese breast cancer patients. PloS One. 2018;13:e0203495–e. https://doi.org/10.1371/journal.pone.0203495.CrossRefPubMedPubMedCentral

20.

Paulo P, Maia S, Pinto C, Pinto P, Monteiro A, Peixoto A, Teixeira MR. Targeted next generation sequencing identifies functionally deleterious germline mutations in novel genes in early-onset/familial prostate cancer. PLoS Genet. 2018;14:e1007355–e. https://doi.org/10.1371/journal.pgen.1007355.CrossRefPubMedPubMedCentral

21.

Lovitt CJ, Shelper TB, Avery VM. Doxorubicin resistance in breast cancer cells is mediated by extracellular matrix proteins. BMC Cancer. 2018;18:41. https://doi.org/10.1186/s12885-017-3953-6.CrossRefPubMedPubMedCentral

22.

Christowitz C, Davis T, Isaacs A, van Niekerk G, Hattingh S, Engelbrecht A-M. Mechanisms of doxorubicin-induced drug resistance and drug resistant tumour growth in a murine breast tumour model. BMC Cancer. 2019;19:757. https://doi.org/10.1186/s12885-019-5939-z.CrossRefPubMedPubMedCentral

23.

Mirzayans R, Andrais B, Murray D. Roles of Polyploid/multinucleated Giant Cancer cells in metastasis and disease relapse following anticancer treatment. Cancers. 2018;10:118. https://doi.org/10.3390/cancers10040118.CrossRefPubMedCentral

24.

Haynes J, Srivastava J, Madson N, Wittmann T, Barber DL. Dynamic actin remodeling during epithelial-mesenchymal transition depends on increased moesin expression. Mol Biol Cell. 2011;22:4750–64. https://doi.org/10.1091/mbc.E11-02-0119.CrossRefPubMedPubMedCentral

25.

J-p L, X-m Z, Zhang Z, Zheng L-h, Jindal S, Liu Y-j. Association of p53 expression with poor prognosis in patients with triple-negative breast invasive ductal carcinoma. Medicine. 2019;98:e15449. https://doi.org/10.1097/md.0000000000015449.CrossRef

26.

Dalmases A, Gonzalez I, Menendez S, Arpi O, Corominas JM, Servitja S, Tusquets I, Chamizo C, Rincon R, Espinosa L, Bigas A, Eroles P, Furriol J, et al. Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-small ka, CyrillicB target genes in human breast cancer. Oncotarget. 2014;5:196–210. https://doi.org/10.18632/oncotarget.1556.CrossRefPubMed

27.

Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol. 2013;230:241–8. https://doi.org/10.1002/path.4188.CrossRefPubMed

28.

Wolczyk D, Zaremba-Czogalla M, Hryniewicz-Jankowska A, Tabola R, Grabowski K, Sikorski AF, Augoff K. TNF-α promotes breast cancer cell migration and enhances the concentration of membrane-associated proteases in lipid rafts. Cell Oncol (Dordr). 2016;39:353–63. https://doi.org/10.1007/s13402-016-0280-x.CrossRef

29.

Katerinaki E, Evans GS, Lorigan PC, MacNeil S. TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer. 2003;89:1123–9. https://doi.org/10.1038/sj.bjc.6601257.CrossRefPubMedPubMedCentral

30.

Wu Y, Zhou BP. TNF-alpha/NF-kappaB/snail pathway in cancer cell migration and invasion. Br J Cancer. 2010;102:639–44. https://doi.org/10.1038/sj.bjc.6605530.CrossRefPubMedPubMedCentral

31.

Kim S, Choi JH, Kim JB, Nam SJ, Yang JH, Kim JH, Lee JE. Berberine suppresses TNF-alpha-induced MMP-9 and cell invasion through inhibition of AP-1 activity in MDA-MB-231 human breast cancer cells. Molecules. 2008;13:2975–85. https://doi.org/10.3390/molecules13122975.CrossRefPubMedPubMedCentral

32.

Martínez-Reza I, Díaz L, García-Becerra R. Preclinical and clinical aspects of TNF-α and its receptors TNFR1 and TNFR2 in breast cancer. J Biomed Sci. 2017;24:90. https://doi.org/10.1186/s12929-017-0398-9.CrossRefPubMedPubMedCentral

33.

Aghaee F, Islamian JP, Baradaran B, Mesbahi A, Mohammadzadeh M, Jafarabadi MA. Enhancing the effects of low dose doxorubicin treatment by the radiation in T47D and SKBR3 breast Cancer cells. J Breast Cancer. 2013;16:164–70. https://doi.org/10.4048/jbc.2013.16.2.164.CrossRefPubMedPubMedCentral

34.

Balaji SA, Udupa N, Chamallamudi MR, Gupta V, Rangarajan A. Role of the drug transporter ABCC3 in breast Cancer Chemoresistance. PLoS One. 2016;11:e0155013. https://doi.org/10.1371/journal.pone.0155013.CrossRefPubMedPubMedCentral

35.

Arányi T, Bacquet C, de Boussac H, Ratajewski M, Pomozi V, Fülöp K, Brampton CN, Pulaski L, Le Saux O, Váradi A. Transcriptional regulation of the ABCC6 gene and the background of impaired function of missense disease-causing mutations. Front Genet. 2013;4:27. https://doi.org/10.3389/fgene.2013.00027.CrossRefPubMedPubMedCentral

36.

Kallergi G, Tsintari V, Sfakianakis S, Bei E, Lagoudaki E, Koutsopoulos A, Zacharopoulou N, Alkahtani S, Alarifi S, Stournaras C, Zervakis M, Georgoulias V. The prognostic value of JUNB-positive CTCs in metastatic breast cancer: from bioinformatics to phenotypic characterization. Breast Cancer Res. 2019;21:86. https://doi.org/10.1186/s13058-019-1166-4.CrossRefPubMedPubMedCentral

37.

Zhang H, Kim JK, Edwards CA, Xu Z, Taichman R, Wang CY. Clusterin inhibits apoptosis by interacting with activated Bax. Nat Cell Biol. 2005;7:909–15. https://doi.org/10.1038/ncb1291.CrossRefPubMed

38.

Peng M, Deng J, Zhou S, Tao T, Su Q, Yang X, Yang X. The role of Clusterin in cancer metastasis. Cancer Manag Res. 2019;11:2405–14. https://doi.org/10.2147/cmar.S196273.CrossRefPubMedPubMedCentral

39.

Niu ZH, Wang Y, Chun B, Li CX, Wu L. Secretory clusterin (sCLU) overexpression is associated with resistance to preoperative neoadjuvant chemotherapy in primary breast cancer. Eur Rev Med Pharmacol Sci. 2013;17:1337–44.PubMed

Title: New insights in gene expression alteration as effect of doxorubicin drug resistance in triple negative breast cancer cells
Authors: Cristina Alexandra Ciocan-Cartita
Ancuta Jurj
Oana Zanoaga
Roxana Cojocneanu
Laura-Ancuta Pop
Alin Moldovan
Cristian Moldovan
Alina Andreea Zimta
Lajos Raduly
Cecilia Pop-Bica
Mihail Buse
Liviuta Budisan
Piroska Virag
Alexandru Irimie
Sandra Martha Gomes Dias
Ioana Berindan-Neagoe
Cornelia Braicu
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Breast Cancer
Breast Cancer
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2020
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-020-01736-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Method

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 1/2020

FadA promotes DNA damage and progression of Fusobacterium nucleatum-induced colorectal cancer through up-regulation of chk2

Correction to: Long non-coding RNA PXN-AS1 suppresses pancreatic cancer progression by acting as a competing endogenous RNA of miR-3064 to upregulate PIP4K2B expression

Novel insights into extrachromosomal DNA: redefining the onco-drivers of tumor progression

Hsa_circ_0003998 promotes epithelial to mesenchymal transition of hepatocellular carcinoma by sponging miR-143-3p and PCBP1

Impact of extracellular matrix stiffness on genomic heterogeneity in MYCN-amplified neuroblastoma cell line

Retraction Note: Long noncoding RNA MLK7-AS1 promotes ovarian cancer cells progression by modulating miR-375/YAP1 axis

Keynote webinar | Spotlight on antibody–drug conjugates in cancer